Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

SCAI 2016, PCI, bleeding risk, bivalirudin, NCDR risk calculator, clinical trial
News | Antiplatelet and Anticoagulation Therapies | May 06, 2016

May 6, 2016 — The largest risk-directed study by a national hospital system demonstrates a 40 percent decline in...

Xarelto, rivaroxaban, PMSS study, ACC 2016, NVAF, atrial fibrillation, stroke
News | Antiplatelet and Anticoagulation Therapies | April 08, 2016

April 8, 2016 — New data from an ongoing post-marketing study confirm the safety profile of Xarelto (rivaroxaban)...

Brilinta, ticagrelor, ACC-AHA guideline, acute coronary syndrome
News | Antiplatelet and Anticoagulation Therapies | April 01, 2016

April 1, 2016 — AstraZeneca confirmed that the American College of Cardiology (ACC) and American Heart Association (...

Photo courtesy of Vital Images

News | ACC | December 22, 2015

December 22, 2015 — In 2015, results from the ITALIC and CvLPRIT trials, along with studies examining lifestyle...

ROCKET AF, executive committee, secondary analysis, rivaroxaban, FDA recall
News | Antiplatelet and Anticoagulation Therapies | December 17, 2015

December 17, 2015 — The ROCKET AF Clinical Trial Executive Committee announced its secondary analysis of the phase...

News | Pharmaceuticals | November 24, 2015

November 24, 2015 —The U.S. Court of Appeals has overturned a federal circuit court’s decision in The Medicines...

Technology | Pharmaceuticals | November 24, 2015

November 24, 2015 – The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals’...

wearable Holter monitors, iRhythm, ziopatch, zio patch

iRhythm Technologies Zio Patch was among the first of a new generation of simplified, wearable Holter monitors designed to increase ease of use and patient compliance to increase detection of arrhythmias that may lead to stroke.

Feature | Holter Monitoring Systems | November 16, 2015 | Judy Lenane, RN, MHA

One-third of ischemic strokes are classified as cryptogenic. The classic risk factors for stroke are usually absent...

News | Antiplatelet and Anticoagulation Therapies | November 12, 2015

November 12, 2015 — Preventing blood clots with drugs such as...

Pradaxa, warfarin, safety and effectiveness, NVAF, non-valvular atrial fibrillation, clinical trial, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies | November 11, 2015

November 11, 2015 — Brigham and Women’s Hospital in Boston and Boehringer Ingelheim announced the results of a new...

pulmonary embolism, low-risk PE, rivaroxaban, Xarelto, MERCURY PE trial

Image courtesy of Philips Healthcare

News | Pulmonary Embolism | November 03, 2015

November 3, 2015 — Pulmonary...

RIVER-PCI trial, ranolazine, incomplete revascularization, ICR, post-PCI, TCT 2015
News | Antiplatelet and Anticoagulation Therapies | October 23, 2015

October 23, 2015 — A randomized trial found that ranolazine did not reduce the composite rate of ischemia-driven...

BRAVO 3 trial results, bivalirudin, heparin, anticoagulation, TAVR, TCT 2015
Feature | Antiplatelet and Anticoagulation Therapies | October 20, 2015

October 20, 2015 — Results from the BRAVO 3 trial found that...

Overlay Init